{"id":"t-pred","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"T-Pred works by inhibiting the production of inflammatory chemicals in the body, which helps to reduce swelling and alleviate symptoms associated with various conditions. It is a type of glucocorticoid, which is a class of steroid hormones that play a crucial role in regulating the immune response.","oneSentence":"T-Pred is a corticosteroid used to reduce inflammation and suppress the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:15.263Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of inflammation and pain in the eye"}]},"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT05896839","phase":"PHASE1, PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":16},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07496229","phase":"PHASE1, PHASE2","title":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","status":"NOT_YET_RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2026-03","conditions":"T-cell Lymphomas","enrollment":165},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT05751941","phase":"PHASE2","title":"Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-02-14","conditions":"Prostate Cancer, Metastatic Prostate Cancer","enrollment":26},{"nctId":"NCT07225946","phase":"PHASE3","title":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-19","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":800},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT02703623","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-18","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":196},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT04569032","phase":"PHASE2","title":"A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-11-12","conditions":"Peripheral T-cell Lymphoma","enrollment":82},{"nctId":"NCT06630091","phase":"PHASE2","title":"A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-21","conditions":"Peripheral T Cell Lymphoma","enrollment":30},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT05818683","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-26","conditions":"Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer","enrollment":277},{"nctId":"NCT04803201","phase":"PHASE2","title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-08","conditions":"Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma","enrollment":170},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04647526","phase":"PHASE3","title":"Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company","startDate":"2021-02-25","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":455},{"nctId":"NCT03808610","phase":"PHASE1, PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT01695005","phase":"PHASE1","title":"A Study of LY3039478 in Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Neoplasms, Neoplasm Metastasis, Lymphoma","enrollment":247},{"nctId":"NCT05996185","phase":"PHASE2","title":"Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-10-09","conditions":"T Cell Lymphoma, T-cell Lymphoma","enrollment":22},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT06421948","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Chidamide in Patients With PTCL","status":"RECRUITING","sponsor":"Yanyan Liu","startDate":"2024-05-25","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT07258680","phase":"PHASE3","title":"BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas","status":"ENROLLING_BY_INVITATION","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2013-10","conditions":"Peripheral T-cell Lymphoma","enrollment":114},{"nctId":"NCT02223208","phase":"PHASE1, PHASE2","title":"Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-09","conditions":"Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic T-cell Lymphoma (AITL)","enrollment":89},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":"Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":48},{"nctId":"NCT06072131","phase":"PHASE3","title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","status":"RECRUITING","sponsor":"Acrotech Biopharma Inc.","startDate":"2023-10-04","conditions":"Peripheral T Cell Lymphoma","enrollment":504},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT03816332","phase":"PHASE1","title":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":12},{"nctId":"NCT06947967","phase":"PHASE3","title":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","status":"RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2025-08-12","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":224},{"nctId":"NCT04709276","phase":"PHASE2","title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Andrew J. Armstrong, MD","startDate":"2021-06-07","conditions":"Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer","enrollment":41},{"nctId":"NCT07168317","phase":"PHASE2","title":"Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-08-01","conditions":"New Diagnosed Angioimmunoblastic T-Cell Lymphoma","enrollment":40},{"nctId":"NCT07035379","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2025-09-01","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":66},{"nctId":"NCT03719105","phase":"EARLY_PHASE1","title":"Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2019-03-01","conditions":"NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma","enrollment":40},{"nctId":"NCT04440267","phase":"PHASE2","title":"Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-07-08","conditions":"Acute Leukemia of Ambiguous Lineage","enrollment":50},{"nctId":"NCT05204927","phase":"PHASE3","title":"177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curium US LLC","startDate":"2022-02-14","conditions":"Metastasis From Malignant Tumor of Prostate","enrollment":439},{"nctId":"NCT05673785","phase":"PHASE2","title":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-02-10","conditions":"Lymphoma","enrollment":52},{"nctId":"NCT07058103","phase":"PHASE2","title":"Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-04-01","conditions":"Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT06474273","phase":"PHASE3","title":"TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"University of Sydney","startDate":"2025-06","conditions":"Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas","enrollment":540},{"nctId":"NCT03384654","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-14","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":47},{"nctId":"NCT06986382","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-07","conditions":"Crohn Disease","enrollment":14},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT03264131","phase":"PHASE2","title":"BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-10-11","conditions":"Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases","enrollment":16},{"nctId":"NCT05958719","phase":"PHASE2","title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-03-02","conditions":"Peripheral T Cell Lymphoma, Epigenetic Repression","enrollment":37},{"nctId":"NCT06739265","phase":"PHASE1, PHASE2","title":"Golidocitinib Plus CHOP in Newly Diagnosed PTCL","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-09-01","conditions":"Peripheral T-cell Lymphoma","enrollment":68},{"nctId":"NCT06701344","phase":"PHASE2","title":"Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-04","conditions":"Enteropathy Associated T Cell Lymphoma","enrollment":7},{"nctId":"NCT06050512","phase":"PHASE1, PHASE2","title":"Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Kathleen Dorritie","startDate":"2023-10-02","conditions":"Relapsed and Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT03586999","phase":"PHASE1, PHASE2","title":"Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-11-07","conditions":"Peripheral T Cell Lymphoma","enrollment":18},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT06433362","phase":"PHASE2","title":"CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-01","conditions":"Peripheral T Cell Lymphoma","enrollment":115},{"nctId":"NCT05075460","phase":"PHASE3","title":"Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"T-cell Lymphoma","enrollment":107},{"nctId":"NCT06347653","phase":"PHASE2","title":"Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)","status":"RECRUITING","sponsor":"Peking University","startDate":"2023-11-28","conditions":"Nodal T-follicular Helper Cell Lymphoma","enrollment":54},{"nctId":"NCT05700565","phase":"","title":"Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype","status":"RECRUITING","sponsor":"Lucie Heinzerling","startDate":"2022-01-01","conditions":"Immune-related Adverse Event","enrollment":50},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT06220487","phase":"PHASE2","title":"A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-02-01","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL","enrollment":67},{"nctId":"NCT05675813","phase":"PHASE1, PHASE2","title":"Genotype-guided Treatment in Newly Diagnosed PTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-13","conditions":"Peripheral T Cell Lymphoma","enrollment":264},{"nctId":"NCT02561273","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-09-28","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma","enrollment":54},{"nctId":"NCT04928066","phase":"PHASE4","title":"The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-03-01","conditions":"Arthritis, Rheumatoid","enrollment":100},{"nctId":"NCT03855007","phase":"PHASE4","title":"The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2016-01-01","conditions":"Arthritis, Rheumatoid","enrollment":400},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT01336933","phase":"PHASE2","title":"Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2011-07-06","conditions":"Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma","enrollment":34},{"nctId":"NCT05320380","phase":"PHASE1, PHASE2","title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2023-08-01","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia","enrollment":""},{"nctId":"NCT05963347","phase":"PHASE2","title":"Go-CHOP as the Frontline Therapy for PTCL","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-08-03","conditions":"Peripheral T Cell Lymphoma","enrollment":45},{"nctId":"NCT03542266","phase":"PHASE2","title":"CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-06-01","conditions":"Previously Untreated Peripheral T-cell Lymphoma","enrollment":21},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00003910","phase":"PHASE2","title":"Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-09-15","conditions":"Leukemia","enrollment":59},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT00217425","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-09-14","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT04480099","phase":"PHASE2","title":"Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-07-29","conditions":"Peripheral T-cell Lymphoma","enrollment":96},{"nctId":"NCT05896813","phase":"NA","title":"CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-03-01","conditions":"Newly Diagnosed Peripheral T-cell Lymphoma","enrollment":30},{"nctId":"NCT04415476","phase":"PHASE2","title":"Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-30","conditions":"Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity","enrollment":""},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"T-cell Non-Hodgkin Lymphoma","enrollment":5},{"nctId":"NCT01796002","phase":"PHASE3","title":"Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-01","conditions":"Peripheral T-cell Lymphoma","enrollment":421},{"nctId":"NCT05678933","phase":"PHASE3","title":"AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":"Peripheral T-cell Lymphoma Targeted Therapy","enrollment":200},{"nctId":"NCT04922567","phase":"PHASE2","title":"Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-04-01","conditions":"Peripheral T-Cell Lymphoma, Lenalidomide, CHOP","enrollment":289},{"nctId":"NCT05239910","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL","status":"WITHDRAWN","sponsor":"Rhizen Pharmaceuticals SA","startDate":"2023-01","conditions":"Peripheral T Cell Lymphoma","enrollment":""},{"nctId":"NCT05572983","phase":"PHASE2","title":"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-09-01","conditions":"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","enrollment":47},{"nctId":"NCT05532111","phase":"NA","title":"Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-09-01","conditions":"Efficacy and Safety","enrollment":60},{"nctId":"NCT03536039","phase":"PHASE2","title":"RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2016-01-27","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":28},{"nctId":"NCT05458180","phase":"PHASE1","title":"CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-07-07","conditions":"Peripheral T-cell Lymphoma","enrollment":18},{"nctId":"NCT03853044","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-12-29","conditions":"Angioimmunoblastic T-cell Lymphoma","enrollment":23},{"nctId":"NCT03551782","phase":"PHASE1","title":"A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-06-28","conditions":"Castration-Resistant Prostatic Neoplasms","enrollment":33},{"nctId":"NCT00069238","phase":"PHASE2","title":"Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-09-19","conditions":"Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell","enrollment":31},{"nctId":"NCT05238064","phase":"PHASE1, PHASE2","title":"Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-03","conditions":"PI3Kδ Inhibitor, Parsaclisib, CHOP","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"T-Pred","genericName":"T-Pred","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"T-Pred is a corticosteroid used to reduce inflammation and suppress the immune system. Used for Treatment of inflammation and pain in the eye.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}